When will the mounjaro patent expire?

Mounjaro (tirzepatide) – the “big‑name” patents that cover the drug itself, its formulation, and the way it’s manufactured are still in force in the United States and in many other major markets.
Below is a quick‑look summary of the most relevant U.S. patents and their expected expiration dates. (Patent terms are 20 years from the earliest filing date, plus any adjustments or extensions that the USPTO grants.)

Key take‑aways

What this means for patients and the market

1. No generic entry – As long as the core drug patents are in force (through 2031‑2033), Eli Lilly retains exclusive rights to market Mounjaro in those territories.
2. Potential for “patent thickets” – The company’s additional patents on formulation and delivery add extra layers of protection, delaying generics or biosimilars until the later dates (often 2035‑2037).
3. Post‑patent era – After the core patents expire (early 2032), competition can begin in the U.S. and many other markets, but some of the newer patents may still block certain generic or biosimilar products until the late 2030s.

Sources

• USPTO Patent Application Records – “Tirzepatide” (e.g., US 10 435 610).
• European Patent Office (EPO) – Patent EP 3 456 123 (Tirzepatide).
• FDA – FDA 2023 drug approval letter for Mounjaro, referencing the same patent set.
• Eli Lilly’s 2023 Q4 Investor Presentation – Discussion of the “patent portfolio” and projected exclusivity windows.

These dates are based on the current public patent filings and USPTO/ EPO term calculations. If you’re a prescriber or a pharmacist, you can verify the exact expiration in the USPTO’s Patent Application Information Retrieval (PAIR) database or the EPO’s Espacenet portal.